Foghorn Therapeutics Inc. (FHTX) News
Follow Foghorn Therapeutics Inc. (FHTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Foghorn Therapeutics Q3 Collaboration Revenue Jumps on Catch-Up Adjustment
EQUITY | Nov 09, 2026, 12:31 PM UTC
M
Foghorn Therapeutics Q3'26 Earnings Preview: EPS Estimate at $(0.24)
Foghorn Therapeutics is scheduled to report Q3'26 results on November 10; the report time is not specified. Revenue is estimated at $7.10 million, with EPS estimated at $(0.24).
EQUITY | Nov 09, 2026, 12:01 PM UTC
M
FHTX Stock Extends Sell-Off After Eli Lilly Collaboration Ends
Foghorn Therapeutics (FHTX) shares dropped over 28% on Friday, extending a previous day's 18% slump, following the termination of its cancer-drug collaboration with Eli Lilly (LLY). The biotech firm announced it would ce
EQUITY | Oct 02, 2026, 06:13 PM UTC
H
Nasdaq Gains 100 Points; ISM manufacturing PMI Slips In September
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.06% to 50,936.24 while the NASDAQ rose 0.37% to 26,960.69. The S&P 500 also rose, gai
LIVE | Oct 01, 2026, 05:54 PM UTC
M
Foghorn Therapeutics Stock Plummets as Eli Lilly Partnership Ends on Cancer Drug
Foghorn Therapeutics (FHTX) shares dropped nearly 45% in pre-market trading after announcing it would discontinue the development of its experimental cancer drug FHD-909, a move made under its partnership with Eli Lilly
EQUITY | Oct 01, 2026, 01:24 PM UTC
H
Foghorn Therapeutics to Cut 40% of Workforce After Drug Discontinuation
Foghorn Therapeutics will cut 40% of its workforce after discontinuing its experimental cancer drug, which was partnered with Eli Lilly. The drug failed to show sufficient benefit in an early-stage trial, and the compani
EQUITY | Oct 01, 2026, 12:11 PM UTC
M
Foghorn Therapeutics Ends Lilly Cancer Drug Trials, Cuts 40% Workforce
Foghorn Therapeutics and Eli Lilly will discontinue joint development of their lead oncology candidate due to disappointing Phase 1 trial results. Foghorn will also reduce its workforce by approximately 40%. Foghorn shar
EQUITY | Oct 01, 2026, 11:40 AM UTC
M
Foghorn Therapeutics Reports Q2 Financials
Foghorn Therapeutics releases Q2 financial update
EQUITY | Aug 06, 2026, 11:00 AM UTC